The classification of glomerulonephritis in systemic lupus erythematosus revisited

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving < 50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving 50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis(i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. the diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification

The classification of glomerulonephritis in systemic lupus erythematosus revisited

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; H, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving &GE;50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions]. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class W and V) should be reported individually in the diagnostic line. the diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1006 AZ Amsterdam, NetherlandsColumbia Univ, Coll Phys & Surg, New York, NY USARush Med Coll, Chicago, IL 60612 USACornell Univ, Weill Med Coll, New York, NY USAUniv Washington, Seattle, WA 98195 USAColumbia Presbyterian Med Ctr, New York, NY 10032 USANIH, Bethesda, MD 20892 USALeiden Univ, Med Ctr, Leiden, NetherlandsImperial Coll Sch Med, London, EnglandSan Carlo Borromeo Hosp, Milan, ItalyVanderbilt Univ, Nashville, TN USASUNY Hlth Sci Ctr, Brooklyn, NY 11203 USAOhio State Univ, Columbus, OH 43210 USAGeorges Pompidou European Hosp, Paris, FranceSt Vincents Hosp, Fitzroy, Vic 3065, AustraliaUniv N Carolina, Sch Med, Chapel Hill, NC USAUniv Kebangsaan Malaysia, Kuala Lumpur, MalaysiaHop Necker Enfants Malad, Paris, FranceUniv Malaya, Sch Med, Kuala Lumpur, MalaysiaOkayama Univ, Grad Sch Med & Dent, Okayama, JapanUniversidade Federal de São Paulo, São Paulo, BrazilUniv Tsukuba, Tsukuba, Ibaraki 305, JapanUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc

The classification of glomerulonephritis in systemic lupus erythematosus revisited

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving 50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis(i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classificatio